Sanofi-aventis, CureDM Ink Global License Agreement On Novel Human Peptide, Pancreate To Treat Diabetes - Quick Facts

Links shared publicly online about this topic.

  • 1,256
    total visits

Sanofi-aventis, CureDM Ink Global License Agreement On Novel Human Peptide, Pancreate To Treat Diabetes - Quick Facts

rttnews.com —

RTTNews delivers all the important global financial news, Market analysis, Economics, stock alerts,forex and any news that may impact individual stocks,specific commodities, currencies and markets as a whole

View full resource at rttnews.com

Tags: Diabetes, Sanofi-Aventis

  • Share

Most Recently Shared on April 8, 2010 at 11:34 am By:

JohnCFierce John Carroll

Sanofi struck a deal to license diabetes peptide from curedm, $335M but no specifics on upfront.Preclinical, backended. http://bit.ly/auz7h3

2 years ago...

Reply

Retweet

Favorite

Advertisement